D-Wave Quantum falls nearly 3% as earnings miss overshadows revenue beat
Investing.com - Cantor Fitzgerald has reiterated an Overweight rating on Wave Life Sciences (NASDAQ:WVE) with a price target of $10.00. The stock has shown strong momentum, gaining over 14% in the past week. According to InvestingPro data, analyst consensus remains highly bullish with targets ranging from $9 to $36.
The firm’s decision follows a virtual webinar hosted with Wave’s CEO Paul Bolno, according to a research note issued by the investment bank.
Cantor Fitzgerald highlighted that the second half of 2025 will be a potentially transformative period for Wave Life Sciences, with several important catalysts on the horizon.
These catalysts include two Phase 2 AATD (Alpha-1 Antitrypsin Deficiency) data updates scheduled for the third quarter of 2025 and Fall 2025, as well as first-in-human obesity data expected in the second half of 2025.
The research note also mentioned that Wave Life Sciences plans to hold its regular R&D event in the fall, which could provide additional insights into the company’s development pipeline.
In other recent news, Wave Life Sciences has been the subject of attention with promising developments in its obesity treatment research. The company presented preclinical data for its candidate, WVE-007, demonstrating significant weight loss in diet-induced obese mice primarily through fat mass reduction, while preserving muscle mass. This data was showcased at the American Diabetes Association’s 85th Annual Scientific Sessions. Analysts at H.C. Wainwright reiterated a Buy rating with a $22 price target, highlighting the potential of WVE-007 in the company’s pipeline. Cantor Fitzgerald also maintained an Overweight rating, citing confidence in Wave’s RNA editing platform and ongoing trials. Both firms emphasize the importance of Wave’s INHBE-targeting approach, which is being evaluated in the Phase 1 INLIGHT clinical trial. Initial clinical data from this trial is expected in the second half of 2025. The company’s innovative strategy in targeting the inhibin Activin E signaling pathway is seen as a key differentiator, with potential implications for weight loss and metabolic health. Wave Life Sciences continues to advance its pipeline of RNA-based treatments, reflecting its ongoing commitment to genetic medicine.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.